Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. - Billings LK; Hsia S; Bays H; Tidemann-Miller B; O'Hagan J; Tham LS; Butler A; Kazda C; Mather KJ; Coskun T (Lancet (London, England), 2025)